Kynurenic acid as a promising therapeutic agent in renal fibrosis: dual modulation of fibrosis and immune crosstalk
British Journal of Pharmacology · 2026-08 · 183 (15) · 4448-4470
DOI: 10.1111/bph.70469 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Pharmacology, online erschienen am 30.04.2026. Verfasst von Sona Sykorova und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University Bratislava, Bratislava, Slovak Republic. Hauptthemen laut MEDLINE: Kynurenic Acid, Kidney Diseases, Kidney. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 80 Literaturangaben. Gefördert von: Ministry of Education, Science, Research and Sport of the Slovak Republic, Slovak Research and Development Agency, Ministerstvo školstva, vedy, výskumu a športu Slovenskej republiky.
Abstract (Originalsprache)
Background and Purpose Renal fibrosis represents a common progressive outcome of various kidney injuries, yet no targeted therapies are currently available. Indoleamine‐2,3‐dioxygenase and its downstream metabolites, kynurenines (KYNs), modulate immune response and may contribute to tissue protection in inflammatory conditions. This study aimed to investigate the potential antifibrotic effects of KYN and kynurenic acid (KYNA). Experimental Approach The effects of KYN and KYNA were investigated in fibroblast culture and in a rat model of unilateral ureteral obstruction‐induced renal fibrosis. Key Results In vitro , both KYN and KYNA effectively inhibited TGF β ‐mediated fibrotic signalling. KYNA suppressed collagen I expression and myofibroblast transdifferentiation. In a rat model of unilateral ureteral obstruction, KYNA reduced fibrotic area, α ‐SMA‐positive regions as well as distal tubular dilatation in cortex and outer medulla. These reno‐protective effects were associated primarily with inhibition of the noncanonical TGF β pathway (pp38, pJNK/JNK) and modulation of the Wnt/ β ‐catenin and JAK2/STAT3 pathways. Furthermore, KYNA influenced proinflammatory NF‐ κ B p65 and shifted the IL‐17A/IL‐10 axis towards a Treg‐dominant profile. KYNA also enhanced fibroblast migration in vitro , suggesting a potential role in promoting wound healing under physiological conditions. Conclusion and Implications KYNA exerts antifibrotic effects both in vitro and in an in vivo model of renal fibrosis. The mechanisms involve multifaceted modulation of key signalling pathways related to fibrosis and immune response, highlighting KYNA as a promising therapeutic candidate for kidney fibrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University Bratislava, Bratislava, Slovak Republic.
Förderung
- Ministry of Education, Science, Research and Sport of the Slovak Republic
- Slovak Research and Development Agency
- Ministerstvo školstva, vedy, výskumu a športu Slovenskej republiky
- Agentúra na Podporu Výskumu a Vývoja
Zitieren
APA
Sykorova, S., Krivy, J., Hadova, K., Kekelakova, A., Vavrinec, P., & Vavrincova-Yaghi, D. (2026). Kynurenic acid as a promising therapeutic agent in renal fibrosis: dual modulation of fibrosis and immune crosstalk. British Journal of Pharmacology, 183(15), 4448-4470. https://doi.org/10.1111/bph.70469
Vancouver
Sykorova S, Krivy J, Hadova K, Kekelakova A, Vavrinec P, Vavrincova-Yaghi D. Kynurenic acid as a promising therapeutic agent in renal fibrosis: dual modulation of fibrosis and immune crosstalk. British Journal of Pharmacology. 2026;183(15):4448-4470. doi:10.1111/bph.70469
BibTeX
@article{Sykorova2026,
author = {Sykorova, Sona and Krivy, Jakub and Hadova, Katarina and Kekelakova, Anna and Vavrinec, Peter and Vavrincova-Yaghi, Diana},
title = {Kynurenic acid as a promising therapeutic agent in renal fibrosis: dual modulation of fibrosis and immune crosstalk},
journal = {British Journal of Pharmacology},
year = {2026},
volume = {183},
number = {15},
pages = {4448--4470},
doi = {10.1111/bph.70469}
}
EUVIMED